Posts by Mourabit Halima

In early September 2024, the 5th Tianjin International Lymphoma Conference was held from September 6 to 8, amid the golden season of autumn. This conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, creating a high-end academic platform for international exchange and collaboration. During the event, Hematology Frontier invited Dr. Jianxiang Wang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College to provide an in-depth analysis of the current state and future trends of CAR-T cell therapy in China from his academic perspective.

The 12th Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) took place in Houston, USA, from September 4 to 7, 2024. It brought together leading experts in hematologic oncology from around the world to discuss the latest research findings and explore new treatment strategies. Among the numerous topics discussed, the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) was a focal point due to the high relapse rate and treatment complexity associated with these diseases. Traditional treatments often fail to provide long-term remission, and CAR-T cell therapy faces the challenge of inadvertently targeting healthy T-cells, further complicating treatment.

With the rapid advancements in medical technology and deeper insights into the mechanisms of lymphoma, traditional chemotherapy is gradually giving way to a new era of precision-targeted and immunotherapies. Innovative drugs are emerging like bamboo shoots after the rain, offering personalized treatment paths tailored to lymphoma patients. This marks the dawn of a new era in disease management, with the promise of more effective and optimistic treatment outcomes. At the 12th Lu Daopei Hematology Forum, Hematology Frontier invited Dr. Hongmei Jing from Peking University Third Hospital to provide a comprehensive analysis of the current state of lymphoma treatment in China, explore future research directions, and discuss the field's ongoing development.

Graft failure is a rare but fatal complication following haploidentical allogeneic hematopoietic stem cell transplantation. A second transplant is almost the only salvage measure for transplant failure. However, outcomes from second transplants have generally been poor, as reported in previous literature. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting was held in Glasgow, UK, from April 14th to 17th, 2024. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, driving better clinical outcomes for patients with blood disorders. At this conference, a team led by Professor Yuqian Sun from Peking University People's Hospital presented their findings in an oral report titled "Salvage Haploidentical Transplantation with Flu/Cy Regimen and Donor Switching After Primary Graft Failure: Follow-Up Results," which garnered significant attention. Professor Sun was invited to share the main results of this study and the progress in salvage treatments for graft failure after haploidentical allogeneic hematopoietic stem cell transplantation.

From June 13th to 16th, 2024, the 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, the capital of Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from all over the world each year to share and discuss innovative concepts and the latest scientific and clinical research achievements in hematology. At this year's EHA conference, several studies from Professor Xufan Zhu's team at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences were selected. This issue highlights two studies on pediatric bone marrow failure diseases (acquired aplastic anemia and Shwachman-Diamond syndrome) and includes insightful commentary from Professor Zhu.